Kali Inc., a US-based medical research company, has announced the launch of the new Kali Cannabis Therapies subsidiary, which will develop cannabis biotechnology treatment alternatives to chemical pharmaceuticals. Last month, it acquired NCM Biotech to include a patented cannabis extraction process and associated intellectual properties consisting of years of preclinical research studies surrounding a multitude of applications of cannabis extracts derived from the patented cannabis extraction process. The acquired cannabis biotechnology intellectual properties will be contained within the new Kali Cannabis Therapies subsidiary where ongoing research and development will be conducted for the purposes of producing cannabis treatments for specific conditions.
Kali-Extracts is releasing summary results of one of many preclinical research studies in order to present an example of the underlying value of Kali-Extracts over cannabis biotechnology intellectual properties. An upcoming independent analyst research report on Kali-Extracts from Goldman Small Cap Research is expected to include a more comprehensive analysis of Kali-Extracts overall body of cannabis biotechnologies.
NCM Biotech (acquired by Kali-Extracts) in collaboration with Beech Tree Labs Inc. (BTL) of Providence, Rhode Island, conducted a series of in vitro genomic experiments to evaluate the potential of cannabis extracts derived from KALY’s patented extraction process in the treatment of respiratory diseases. The ability of various formulations to change Asthma or chronic obstructive pulmonary disease (COPD) associated gene expressions in human small airway epithelial cells were evaluated during the experiments. Genes appearing especially sensitive to the introduction of cannabis extract were associated with inflammation, healing and cancer inhibition. The results from this series of experiments provided a baseline for comparison with data from subsequent studies.
As per WHO, 65 million people have moderate to severe COPD with three million deaths annually. The treatment of COPD is currently estimated to be $5 billion in the United States and $11 billion worldwide. If therapeutic agents with less severe side effects were introduced, the market would grow significantly as side effects prevent many COPD patients from using currently approved drugs.
“I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognised by the market,” said Frederick Ferri, CEO of Kali-Extracts. “Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals (GW Pharmaceuticals plc (NASDAQ: GWPH)). As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex (Generex Biotechnology, Corp. (OTCQB: GNBT)) through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex’s RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be relised value. Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets.”
